ProCE Banner Activity

EMBRACE: Phase IIb Study of VH3810109 (N6LS) in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

EMBRACE study suggests switch to N6LS, a novel broadly neutralizing antibody, was effective and well tolerated when administered intravenously every 4 months in combination with long-acting cabotegravir.

Released: March 18, 2025

Expiration: September 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare